The reported increase in costs for CVS Health due to seasonal immunizations, including the RSV vaccine, could pressure the company's short-term profitability. Additionally, the cautious stance on the 2024 outlook for Medicare Advantage utilization suggests uncertainty about future revenue streams from this segment. Both factors are likely to influence investor sentiment negatively in the short term.